TRAVERE THERAPEUTICS, INC. Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs
TRAVERE THERAPEUTICS, INC. (TVTX) had Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs of $9 as of 2012-12-31, per its 10-K/A filed 2013-09-16.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross › Deferred Tax Liabilities, Deferred Expense
us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts · last filed 2013-09-16
- 2012-12-31: Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs $9.00.
| Period end | Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs |
|---|---|
| 2012-12-31 | $9.00 10-K/A · filed 2013-09-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |